Binding of Macrolide Antibiotics Leads to Ribosomal Selection against Specific Substrates Based on Their Charge and Size  by Sothiselvam, Shanmugapriya et al.
ReportBinding of Macrolide Antibiotics Leads to Ribosomal
Selection against Specific Substrates Based on Their
Charge and SizeGraphical AbstractHighlightsd Macrolide antibiotics induce ribosome stalling at Arg/Lys-
X-Arg/Lys motifs
d The size and charge of key residue side chains hinder peptide
bond formation
d Properties of the nascent protein affect the catalytic capacity
of the ribosomeSothiselvam et al., 2016, Cell Reports 16, 1789–1799
August 16, 2016 ª 2016 The Authors.
http://dx.doi.org/10.1016/j.celrep.2016.07.018Authors
Shanmugapriya Sothiselvam,
Sandro Neuner, Lukas Rigger,
Dorota Klepacki, Ronald Micura,
Nora Va´zquez-Laslop,
Alexander S. Mankin
Correspondence
nvazquez@uic.edu (N.V.-L.),
shura@uic.edu (A.S.M.)
In Brief
Macrolide antibiotics stall ribosomes at
the Arg/Lys-X-Arg/Lysmotif. Sothiselvam
et al. find that the charge and size of key
amino acid side chains in this motif make
peptide bond formation inefficient.
Antibiotics greatly magnify the problemof
these intrinsically difficult donor-
acceptor pairs.
Cell Reports
ReportBinding of Macrolide Antibiotics Leads
to Ribosomal Selection against Specific
Substrates Based on Their Charge and Size
Shanmugapriya Sothiselvam,1 Sandro Neuner,2 Lukas Rigger,2 Dorota Klepacki,1 Ronald Micura,2
Nora Va´zquez-Laslop,1,* and Alexander S. Mankin1,*
1Center for Biomolecular Sciences, University of Illinois, Chicago, IL 60607, USA
2Institute of Organic Chemistry and Center for Molecular Biosciences, Leopold Franzens University, 6020 Innsbruck, Austria
*Correspondence: nvazquez@uic.edu (N.V.-L.), shura@uic.edu (A.S.M.)
http://dx.doi.org/10.1016/j.celrep.2016.07.018SUMMARY
Macrolide antibiotic binding to the ribosome inhibits
catalysis of peptide bond formation between specific
donor and acceptor substrates. Why particular
reactions are problematic for the macrolide-bound
ribosome remains unclear. Using comprehensive
mutational analysis and biochemical experiments
with synthetic substrate analogs, we find that the
positive charge of these specific residues and the
length of their side chains underlie inefficient peptide
bond formation in the macrolide-bound ribosome.
Even in the absence of antibiotic, peptide bond for-
mation between these particular donors and accep-
tors is rather inefficient, suggesting that macrolides
magnify a problem present for intrinsically difficult
substrates. Our findings emphasize the existence of
functional interactions between the nascent protein
and the catalytic site of the ribosomal peptidyl trans-
ferase center.INTRODUCTION
The ribosome is an incredibly complex and sophisticated protein
synthesismachine that represents one of themajor antibiotic tar-
gets in bacterial cells (Wilson, 2009). Although many ribosome-
targeting inhibitors completely abolish protein synthesis, some
of them interfere with translation in a context-specific manner.
Macrolides, such as erythromycin (ERY) and its derivatives,
represent the best-studied examples of inhibitors whose action
critically depends on the amino acid sequence of the synthe-
sized protein (Davis et al., 2014; Hardesty et al., 1990; Kannan
et al., 2012, 2014; Starosta et al., 2010). Depending on the nature
of the nascent chain and the structure of the drug, synthesis of
the polypeptide can be arrested during very early rounds (Otaka
and Kaji, 1975; Tenson et al., 2003), at the later stages of
translation elongation (Davis et al., 2014; Kannan et al., 2014),
or not at all (Kannan et al., 2012; Starosta et al., 2010). Although
optimizing clinical outcomes of antibiotic therapy hinges on
achieving an understanding of the mode of drug action, a mech-Cell R
This is an open access article under the CC BY-Nanistic explanation for the context specificity of macrolides is
lacking.
Macrolide antibiotics target the large ribosomal subunit. The
drugs bind in the nascent peptide exit tunnel (NPET) at a short
distance from the peptidyl transferase center (PTC). Binding of
the antibiotic obstructs the NPET and restricts placement of
the nascent chain in the tunnel and its progression from the
PTC to the tunnel exit (Bulkley et al., 2010; Dunkle et al., 2010;
Schl€unzen et al., 2001; Tu et al., 2005). When the newly synthe-
sized peptide chain grows to around four amino acids, it reaches
the site of antibiotic binding (Arenz et al., 2014a, 2014b). Synthe-
sis of some proteins by the drug-bound ribosome is interrupted
at this stage, especially when the macrolide, like ERY, contains a
C3-bound cladinose sugar that protrudes into the lumen of the
tunnel (Bulkley et al., 2010; Dunkle et al., 2010; Schl€unzen
et al., 2001). However, some nascent peptides are able to
bypass the antibiotic, allowing their continued synthesis in spite
of the presence of a bulky drug molecule in the NPET (Hardesty
et al., 1990; Kannan et al., 2012; Starosta et al., 2010). Ketolide
drugs, which lack a C3 cladinose, rarely inhibit translation at
the early stages, and synthesis of many proteins continues
past the initial rounds of protein elongation (Kannan et al.,
2012, 2014).
Although macrolides do not inhibit synthesis of many proteins
at the early rounds, translation of the majority of polypeptides by
the drug-bound ribosome is eventually interrupted at the later
stages of elongation (Davis et al., 2014; Kannan et al., 2014).
Strikingly, abrogation of translation does not occur randomly,
but, rather, drug-bound ribosomes become arrested at specific,
well definedmRNA sites. Ribosome profiling analysis carried out
in Gram-positive and Gram-negative bacteria treated with mac-
rolides helped identify the major sites of late translation arrest
and allowed for initial classification of problematic sequences
(Davis et al., 2014; Kannan et al., 2014). Several amino acid mo-
tifs conducive to macrolide-induced arrest emerged from these
studies. One of the most prevalent motifs conforms to the
consensus R/K-X-R/K, where R and K represent arginine and
lysine, respectively, and X represents any amino acid. In vitro
biochemical testing supported the conclusion drawn from the
profiling analysis that the ribosome stalls when the codon
specifying the middle amino acid (X) of the motif enters the
P site. Accordingly, the first residue of the consensus (R or K)eports 16, 1789–1799, August 16, 2016 ª 2016 The Authors. 1789
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
represents the penultimate amino acid of the nascent peptide
chain, whereas the last consensus sequence residue (also
R or K) corresponds to the A site-bound aminoacyl-tRNA (Davis
et al., 2014; Kannan et al., 2014; Sothiselvam et al., 2014).
Importantly, the context specificity of antibiotic action is ex-
ploited for the regulation of expression of resistance genes (re-
viewed in Weisblum, 1995). The inducible macrolide resistance
genes remain silent in the absence of the antibiotic but are acti-
vated in its presence. Activation relies on programmed ribosome
stalling at a precise, evolutionarily defined site of the regulatory
upstream open reading frame (uORF) that precedes the resis-
tance gene (Ramu et al., 2009; Subramanian et al., 2011; Weis-
blum, 1995). The ribosomes arrested at the uORF alter the
folding of the mRNA, activating the expression of the down-
stream resistance cistron. The structure of the antibiotic and
the sequence of the leader peptide are the two main factors
that determine the site of programmed translation arrest (Arenz
et al., 2014a, 2014b; Gryczan et al., 1980; Horinouchi and Weis-
blum, 1980; Ramu et al., 2011; Va´zquez-Laslop et al., 2008,
2010). Strikingly, the R/K-X-R/K sequence, identified as one of
the major motifs of macrolide-induced translation arrest (Davis
et al., 2014; Kannan et al., 2014), is present in many of the regu-
latory uORFs of macrolide resistance genes, including the well-
studied ermDL ORF that controls expression of the ermD gene
(Kwak et al., 1991; Kwon et al., 2006; Sothiselvam et al., 2014).
In all tested regulatory uORFs with the R/K-X-R/Kmotif, the ribo-
some stalls when the second codon of the consensus enters the
ribosomal P site (Almutairi et al., 2015; Sothiselvam et al., 2014).
Strikingly, in the stalled ribosome, the amino acid residues of
the R/K-X-R/K motif are located at the PTC active site rather
than being juxtaposed next to the antibiotic molecule bound in
the NPET (Arenz et al., 2014a, 2014b). Similarly, other stalling
motifs identified in ribosome profiling experiments were also
confined to the C-terminal residues of the nascent chain and
the incoming amino acid (Davis et al., 2014; Kannan et al.,
2014). These observations led to the conclusion that, at least
at the late elongation stage, macrolides do not hinder translation
by simply barricading the NPET but, rather, act as context-spe-
cific PTC inhibitors (Kannan et al., 2014). Indeed, RNA chemical
probing showed that binding of macrolides to the NPET of the
vacant ribosome was sufficient to allosterically induce structural
changes in the PTC (Sothiselvam et al., 2014). In agreement with
this view, translation of the 50 terminally truncated ermDL ORF,
which encodes the peptide starting with the MRLR sequence,
was efficiently arrested by macrolides at the Leu3 codon,
when the nascent chain was only three amino acids long and
had only limited contacts with the drug. These results suggested
that inhibition of translation elongation by macrolides does not
necessarily require blocking the progression of the nascent
chain in the drug-obstructed NPET but, rather, that binding of
the antibiotic allosterically renders the PTC more restrictive to-
ward its substrates, thus predisposing the ribosome for transla-
tion arrest when certain combinations of donors and acceptors
meet at the catalytic center (Kannan et al., 2014; Sothiselvam
et al., 2014).
Despite the importance of understanding the precise molecu-
lar mechanisms of antibiotic action for the development of better
drugs and for the exploration of ribosome functions, the basis for1790 Cell Reports 16, 1789–1799, August 16, 2016macrolide specificity remains obscure. It is poorly understood
why certain combinations of donor and acceptor substrates,
defined by the identified consensus sequences, are troublesome
for the drug-bound ribosome. In particular, for the translation
arrest directed by the R/K-X-R/K sequence, one could envision
that either the positive charge or the extended length of the
side chains of the arginine and lysine residues of the motif could
be the dominant factor contributing to stalling. It is also unclear
whether the binding of macrolide antibiotics to the ribosome
causes some normally ‘‘easy’’ substrates to become ‘‘difficult’’
or whether the drugs simply exacerbate the challenging nature
of intrinsically problematic substrates.
To gain further mechanistic insight into the mode of action of
macrolide antibiotics, in this work we investigated the effect of
the drug on the ability of the ribosome to catalyze the transfer
of the short nascent MRL peptide to acceptor substrates that
differ in their physicochemical properties. The lack of an
extended nascent chain in this stalled complex allowed us to
minimize the contribution of the context preceding the stalling
motif on translation arrest (Davis et al., 2014; Elgamal et al.,
2014; Kannan et al., 2014; Starosta et al., 2014; Woolstenhulme
et al., 2013). We found that two factors, the length of the side
chains of the amino acid residues in the donor and acceptor sub-
strates and, even more importantly, the positive charge of the
critical residues, contribute to macrolide-induced arrest. Inter-
estingly, our results indicate that the model substrates that react
extremely slowly in the presence of antibiotic appear to be prob-
lematic donor-acceptor pairs even for the drug-free ribosome.
RESULTS
Antibiotic-Mediated Translation Arrest at theMRLRORF
Is Independent of the mRNA Sequence and tRNA
Structure
Our previous experiments showed that macrolide antibiotics ar-
rest translation of the truncated ermDL gene (MRLR.) when the
Leu3 codon is placed in the ribosomal P site and the Arg4 codon
enters the decoding site (Sothiselvam et al., 2014). To test
whether macrolide-induced ribosome stalling is influenced by
the structures of mRNA or tRNA, we changed codons 2–4 of
the truncated ermDL template to several different combinations
of synonymous triplets that not only alter the mRNA sequence
but also direct binding of different aminoacyl-tRNA isoacceptors
(Figure S1A). Toeprinting analysis showed that these alterations
in mRNA sequence hadminimal effects on the efficiency of ERY-
directed arrest (Figure S1A). Therefore, neither the mRNA
sequence nor the structure of the tRNA body affect macrolide-
dependent ribosome stalling at the truncated ermDL ORF, leav-
ing the nature of the nascent peptide sequence as the likely
primary determinant of translation arrest.
Only the Templates Encoding Arg or Lys in the Second
and Fourth Codons Are Conducive to ERY-Induced
Translation Arrest
In the ribosome stalled at the truncated ermDL template, the
MRL tripeptide esterifies the P site tRNALeu, and the A site codon
specifies for Arg-tRNA. We wanted to understand how the
chemical nature of the peptidyl donor and aminoacyl acceptor
Figure 1. Amino Acid Residues Critical for ERY-Dependent Trans-
lation Arrest in the MRLR ORF
(A–C) Toeprinting analysis of ERY-dependent ribosome stalling in the MRLR
ORFs. The codons specifying the residues of the RLR motif located in the
penultimate (1) position of the MRL tripeptide (A), the peptide’s C-terminal
residue located in the PTC P site (B), or the amino acid to be placed in the A site
(C) weremutated to code for each of the other 19 canonical amino acids. Black
arrows indicate toeprint bands representing ERY-dependent translation arrest
at the third codon. Lanesmarked represent the reactions with wild-type (WT)
template but lacking ERY. Gray arrows point to the toeprint bands corre-
sponding to the ribosomes, which bypassed the third codon and were
captured at the downstream Pro6 codon because of the presence of mupir-
ocin, an IleRS inhibitor. In the case of Ile mutations in the MRLR peptideaffects catalysis of peptide bond formation by the drug-bound
ribosome. First, we investigated the contributions of the second
and third amino acids of the peptidyl moiety of the donor sub-
strate, MRL-tRNA, to macrolide-dependent translation arrest.
Codons 2 and 3 of the MRLR ORF, which encode the penulti-
mate and the C-terminal residues of the nascent peptide, were
mutated to specify all other 19 amino acids, and ERY-induced
ribosome stalling in these templates was analyzed by toeprint-
ing. Most of the alterations of the penultimate amino acid
(Arg2) abolished stalling. Only the Arg2-to-Lys replacement
maintained efficient translation arrest (Figure 1A). In contrast,
the nature of the C-terminal residue was of much lesser impor-
tance. Only changes of Leu3 to Trp or Pro showed a somewhat
increased bypass of the arrest site, whereas the majority of the
mutants directed ribosome stalling as readily as the wild-type
sequence (Figure 1B).
We then examined the role of the acceptor substrate. By
mutating the fourth codon of theMRLRORF,we directed binding
of aminoacyl-tRNAs linked to each of the 20 different amino
acids to the ribosomal A site. Similar to the effect observed for
the penultimate position of the nascent peptide, only the Arg4-
to-Lys (and, to a much lesser extent, the Arg4-to-Trp) substitu-
tion was conducive to ERY-induced stalling (Figure 1C). Thus,
ERY promotes the formation of a stable stalled ribosome com-
plex preferentially on those short templates where the second
and fourth codons specify either Arg or Lys.
Because individual substitutions of Arg2 or Arg4 with Lys were
compatible with ERY-induced stalling, we also tested whether
simultaneous replacement of both Arg codons with Lys would
still support translation arrest. Indeed, we found that the majority
of the ribosomes that reached the third codon of the MKLK tem-
plate became arrested (Figure S1B, black arrowheads, lane L). In
addition, similar to the results obtained with the MRLR template,
mutations of the Leu3 codon, sandwiched between the two Lys
codons in the MKLK template, had little effect on ERY-induced
arrest (Figure S1B). An exception was the MKPK sequence. In
this template, drug-bound ribosomes could not reach the third
codon because they stalled at the Lys2 codon (Figure S1B,
lane P), likely because of the reported propensity of macrolides
to inhibit peptide bond formation between a donor peptide
with a C-terminal lysine and prolyl-tRNA (Davis et al., 2014;
Kannan et al., 2014).
Altogether, our mutational studies showed that the antibiotic
bound in the ribosomal exit tunnel efficiently and specifically pre-
vents the transfer of nascent tripeptides that have an Arg or Lys
as their penultimate residues to an Arg or Lys acceptor
(Figure 1D).(lanes I), the Ile7 codon was replaced with the Trp codon, and mupirocin was
substituted with indlomycin, a TrpRS inhibitor. Symbols representing amino
acids conducive to ERY-dependent arrest are shown in bold. Sequencing
lanes are marked C, U, A, and G. The gels shown are representative of two
independent experiments.
(D) Representation of the ERY-stalled ribosome with the tripeptidyl MRL-
tRNALeu in the P site and aminoacyl-tRNA in the A site. Amino acid residues
critical for drug-dependent ribosome stalling are depicted by red spheres, and
the antibiotic molecule is indicated by a star.
See also Figures S1 and S2.
Cell Reports 16, 1789–1799, August 16, 2016 1791
Table 1. Reactivity of Acceptor Substrate Analogs with the MRL-
tRNA and MAL-tRNA Donors in the ERY-Bound and Drug-free
Ribosome
Acceptor Substrate (a)
Donor Substrate
MRL MAL
No drug
kapp (min-1)
ERY
kapp (min-1)
No drug
kapp (min-1)
ERY
kapp (min-1)
L-arginine [6]
0.09 ± 0.15 0.01 ± 0.02 0.96 ± 0.23 0.87 ± 0.21
L-lysine [5]
0.15 ± 0.03 0.01 ± 0.01 0.74 ± 0.14 1.17 ± 0.23
L-ornithine [4]
0.08 ± 0.02 < 0.01 b) 1.03 ± 0.29 0.81 ± 0.22
L-aminoalanine [2]
> 1.8 * c) 0.61± 0.16 ND d) ND
6-azido-L-norleucine [7]
> 1.8 * 0.32 ± 0.08 > 1.8 * > 1.8 *
5-ethyl-L-norleucine [6]
> 1.8 * 0.31 ± 0.07 > 1.8 * > 1.8 *
6-hydroxy-L-norleucine [5]
> 1.8 * 0.34 ± 0.10 > 1.8 * > 1.8 *
L-norleucine [4]
> 1.8 * > 1.8 * > 1.8 * > 1.8 *
L-alanine [1]
> 1.8 * > 1.8 * > 1.8 * > 1.8 *
NH
NH2
NH2+
NH2
NH3+
NH2
NH3+
NH2
NH2
NH3+
N N+ N-
NH2
NH2
OH
NH2
NH2
NH2
ND, not determined.
aAcceptor substrates conform to the general formula pACCA-N-X, where
X corresponds to different canonical or non-canonical amino acids. The
pACCA-N moiety of the substrates is represented by a sphere, and the
chemical structure of the aminoacyl residue is shown. The names of
the substrates whose side chain carries a positive charge are shown in
red, and the substrates with a neutral net charge of the side chain are
shown in green. The number of non-hydrogen atoms in the side chain
skeleton is indicated in brackets next to the substrate name.
bThe reaction was too slow to accurately determine its kapp.
cReaction rates with kapp exceeding 1.8 min
1 could not be measured in
the experimental setup used for the kinetics experiments. The kapp values
for the corresponding reactions are indicated as >1.8 and are marked by
an asterisk.The Presence of Arg or Lys in the Donor and Acceptor
Substrates Is Critical for Translation Arrest Prompted by
Diverse Macrolide Antibiotics
Stalling peptides that regulate expression of erm genes
often exhibit strong selectivity toward macrolide antibiotics
containing C3 cladinose (e.g., ERY) but do not respond to
cladinose-lacking ketolides (Va´zquez-Laslop et al., 2011;
Va´zquez-Laslop et al., 2008). In contrast, both cladinose-
containing macrolides as well as ketolides arrest translation
of the truncated ErmDL (Sothiselvam et al., 2014). We asked1792 Cell Reports 16, 1789–1799, August 16, 2016whether the identity of the second and fourth codons of the
MRLR template, which is critical for ERY-induced arrest (Fig-
ure 1), is also important for ribosome stalling directed by other
macrolide antibiotics. Therefore, we tested the response of
ErmDL mutants to the fluoroketolide solithromycin (SOL) and
the cladinose-containing 15-member ring azithromycin (AZI)
(Figure S2A).
Similar to the effects observed with ERY, the mutation of Arg2
or Arg4 to Ala completely abolished arrest induced by SOL or
AZI. Furthermore, similar to the effect on ERY-mediated arrest,
altering the third codon (Leu) to Ala allowed for efficient arrest
directed by AZI or SOL (although this mutation caused some
read-through of the SOL-bound ribosome) (Figure S2B). We
concluded that the nature of the penultimate residue of the
short nascent peptide and the incoming amino acid are the
most critical for arrest induced by a broad range of macrolide
antibiotics.
Antibiotic Exacerbates the Difficulty of Peptide Bond
Formation between Intrinsically Problematic Ribosomal
Substrates
The results presented above strongly suggest that the ribo-
some with a macrolide antibiotic bound in the exit tunnel stalls
when it needs to catalyze the transfer of tripeptides MRX or
MKX to an Arg or Lys acceptor. To substantiate this
conclusion, we followed the kinetics of peptide bond formation
between the donor MRL-tRNA and different model acceptor
substrates. For these experiments, we synthesized chemically
stable substrates mimicking the aminoacyl-tRNA acceptor
end (Graber et al., 2010; Moroder et al., 2009; Table 1). In
these aminoacyl-tRNA analogs with the general structure
ACCA-X, various amino acid residues (X) were linked to the
30 carbon atom of the universal tRNA sequence ACCA via a
stable amide bond (Supplemental Information). Binding of
these substrates to the ribosomal A site does not require the
elongation factor EF-Tu or interaction with the mRNA codon
in the decoding center, and their acceptor ability depends
exclusively on the nature of the amino acid residue. In
the initial series of experiments, we used analogs that
contained canonical amino acid residues that are either
conducive to stalling (X = Arg or Lys) or abolish the arrest
(X = Ala) (Table 1).
The ribosome/mRNA/MRL-tRNA complex was prepared by
translating the MRL peptide from a synthetic tri-codon
mRNA in the PURE cell-free translation system (Shimizu
et al., 2001). Because the mRNA lacks a stop codon, the
ribosome stalls at the third codon carrying the tripeptidyl
MRL-tRNALeu bound in the P site and a vacant A site regard-
less of the presence of ERY (Figure 2A). The stalled ribosome
complexes were then mixed with high concentrations (0.7 mM)
of the acceptor substrates, and the progression of the peptidyl
transfer reaction was monitored by quantifying the amount of
unreacted MRL-tRNALeu resolved in Bis-Tris polyacrylamide
gels (Figure 2B; Figure S3A). Upon addition of the ACCA-N-
Ala acceptor substrate, irrespective of the presence of ERY,
the reaction was completed within 30 s (the shortest incuba-
tion time we could reliably measure with our experimental
setup) (apparent rate constant kapp > 1.8 min
1) (Figures 2B
Figure 2. Arg and Lys Are Poor Acceptors of
the MRL Peptide in the Stalled Ribosome
(A and D) Schematic depicting the experimental
design. ERY-bound ribosomes carrying MRL-
tRNALeu (A) or MAL-tRNALeu (D) in the P site and an
empty A site are reacted with the model A site
substrates ACCA-N-Arg and ACCA-N-Lys (red
circles) or ACCA-N-Ala (green circle). Antibiotic
bound in the NPET is represented by a star.
(B and E) Gel electrophoresis analysis of the 35S-
labeled MRL-tRNALeu (B) or MAL-tRNALeu (E)
(marked by peptidyl-tRNA drawings) remaining
unreacted upon addition of ACCA-N-Ala, ACCA-
N-Lys, or ACCA-N-Arg. The band corresponding
to fMet-tRNAfMet present in the reaction is indi-
cated by a triangle. Gels are representative of at
least two independent experiments.
(C and F) Results of the quantification of the
amount of unreacted MRL-tRNALeu (C) or MAL-
tRNALeu (F) in the gels shown in (B) and (E),
respectively. The amount of unreacted peptidyl-
tRNA at the 0 time point was set as 100%. Error
bars show deviation from the mean in two inde-
pendent experiments for each donor substrate.
See also Figure S3.and 2C; Table 1). This indicates that both the drug-free and
ERY-bound ribosomes efficiently catalyze transfer of MRL to
the non-stalling Ala acceptor. In striking contrast, in the pres-
ence of ERY, the majority of MRL-tRNALeu remained unreacted
with the ACCA-N-Arg or ACCA-N-Lys acceptors after 30 min
of incubation (Figures 2B and 2C). Interestingly, although the
absence of the antibiotic caused the reaction with these
analogs to accelerate nearly 10-fold (kapp = 0.9–1.5 min
1), it
remained notably slower in comparison with the ACCA-N-Ala
substrate (Figures S3A and S3B; Table 1). The marked reduc-
tion in the reaction rate between MRL-tRNA and ACCA-N-Arg
or ACCA-N-Lys acceptors in the absence of antibiotics was
not manifested in the conventional toeprinting experiments
(no-antibiotic lanes, Figures 1A–1C), likely because the puta-
tive ribosome pausing was too transient to be captured by
this assay. Nevertheless, the results of biochemical testing
clearly show that the transfer of the MRL donor to the Arg or
Lys acceptors is intrinsically difficult for the ribosome and
that the presence of the antibiotic in the exit tunnel dramati-
cally intensifies the problem, essentially halting peptide bond
formation.Cell RepThe Positive Charge of the A Site
Substrates Is the Predominant
Factor that Makes Them Poor
Acceptors of the MRL Peptide
Arg and Lys are unique among the 20
canonical amino acids because they
contain the longest side chains, which
are positively charged at physiological
pH. We considered that the size, the
charge, or the combination of these two
features could make it difficult for the
ribosome to use Arg-tRNA or Lys-tRNAas acceptors of the MRL peptide, hence leading to translation
arrest. To dissect the contribution of length and charge of the
acceptor’s side chain to antibiotic-mediated ribosome stalling,
we prepared a new series of synthetic substrate analogs that
varied in the length of the side chain and in the presence or
absence of the positive charge (Table 1). We then tested the
acceptor activity of these substrates in the same experimental
setup we used before with the Ala, Lys, or Arg acceptor analogs.
In the presence of ERY, the transfer of theMRL peptide to ACCA-
N-6-azido-L-norleucine, ACCA-N-6-hydroxy-L-norleucine, or
ACCA-N-6-ethyl-L-norleucine, whose side chain skeletons
range in length from five to seven non-hydrogen atoms but
lack the net positive charge, occurs with the apparent rate
constant kapp of 0.3 min1 (Figure 3; Table 1). Remarkably,
shortening the uncharged side chain to four carbon atoms (in
ACCA-N-norleucine) significantly accelerated the reaction, mak-
ing it too fast to accurately determine the rate constant in our
experiments (kapp > 1.8 min
1) (Figure 3; Table 1). Likewise, in
the absence of the antibiotic, all uncharged acceptor substrates
reacted with kinetics too rapid to be accurately measured (Fig-
ure S3B; Table 1). These results showed that the length of theorts 16, 1789–1799, August 16, 2016 1793
Figure 3. The Positive Charge and Extended Size of the Acceptor
Amino Acid Side Chain Prevent Efficient Peptide Bond Formation
with the MRL Peptide in ERY-Bound Ribosomes
(A and B) Kinetics of the reaction of the MRL-tRNALeu in the P site of ERY-
bound ribosomes (as illustrated in the schematic in Figure 2A), with acceptor
substrate analogs carrying non-canonical amino acids. The quantification of
the amount of unreacted MRL-tRNALeu is from the gels shown in Figure S5.
The amount of unreacted MRL-tRNALeu at the 0 time point was set as 100%.
Error bars show deviation from the mean calculated from two independent
experiments. The 30-min time point for the ACCA-N-aminoalanine substrate
was assayed in a single experiment. The reactivity plots of the substrate
analogs with canonical amino acids (Arg, Lys, and Ala) are those from Fig-
ure 2C and are shown here by dashed lines for comparison.acceptor side chain contributes to the arrest mechanism
because macrolides notably slow down the transfer of the
MRL peptide with acceptors having extended side chains.
Nevertheless, the reaction of the MRL peptide with electroneu-
tral acceptors still proceeded at a considerable rate, indicating
that the extended length of the acceptor side chain is insufficient
to support formation of a stable stalled complex.
Introduction of the positive charge to the side chain on the
acceptor substrate exhibited a more dramatic effect on the rate1794 Cell Reports 16, 1789–1799, August 16, 2016of reaction with the MRL donor. Replacement of the terminal
methyl group of norleucinewith a positively charged amino group
in ACCA-N-ornithine resulted in a precipitous drop of the MRL
transfer rate, essentially abolishing the reaction in the presence
of ERY (kapp < 0.01 min
1) (Figure 3; Table 1). In addition, consis-
tent with what was observed for Arg and Lys acceptors, even in
the absence of ERY, the transfer of the MRL peptide to ACCA-
N-ornithine was rather inefficient (kapp = 0.08 ± 0.02 min
1) (Fig-
ure S3B; Table 1). These results clearly indicate that the major
obstacle for catalysis of the transfer of the MRL peptide to the
acceptor in thePTCof themacrolide-bound ribosome is imposed
by the charge of the A site amino acid. However, in agreement
with the notion of the importance of the size of the side chain,
ACCA-N-aminoalanine, with a positively charged side chain as
short as two non-hydrogen atoms, reacted faster than any of
the other tested positively charged acceptors (kapp = 0.61 ±
0.16min1) (Figure 3; Table 1) butmuchslower thananyof the un-
charged substrates with a side chain shorter than five atoms.
The sluggish transfer of the MRL peptide to the positively
charged substrates ACCA-N-Lys, ACCA-N-Arg, and ACCA-N-
ornithine critically depends on the presence of Arg (or Lys) in
the penultimate position of the nascent chain. The non-stalling
donor peptide MAL swiftly reacted with the acceptor substrates
containing Ala, Lys, or Arg residues irrespective of the presence
of antibiotic (kapp R 0.74 min
1) (Figures 2D–2F; Figures S3C
and S3D; Table 1). Consequently, removal of the long, positively
charged side chain of the penultimate residue of the donor sub-
strate allows for efficient peptidyl transfer even to positively
charged A site substrates. Thus, it appears that the simultaneous
presence of the charged long side chains in the penultimate po-
sition of the donor substrate and in the aminoacyl acceptor pre-
sent the obstacle for catalysis of peptide bond formation by the
macrolide-bound ribosome.
One possiblemodel that follows from our findings is that a sim-
ple electrostatic repulsion between the penultimate residue of
the peptidyl donor and the aminoacyl moiety of the acceptor
may be sufficient to hamper the catalysis of the peptidyl transfer
reaction in the macrolide-bound ribosome. If this were the case,
then simultaneous replacement of the positively charged resi-
dues encoded in codons 2 and 4 of the MRLR ORF with nega-
tively charged amino acids would be comparably detrimental
for translation. We tested this hypothesis in a straightforward
toeprinting experiment exploiting two new templates in which
the second and the fourth codons of the MRLR ORF were
mutated to specify peptides MDLD and MELE, which carry
negatively charged amino acids in the critical positions (Figure 4).
However, neither of these peptides were able to direct efficient
arrest of the macrolide-bound ribosome. Thus, it is not the sim-
ple repulsion of two equivalent charges but the explicit presence
of positive charges at the extended side chains of the penulti-
mate residue of the P site peptidyl donor and of the A site amino-
acyl acceptor that obstructs peptide bond formation in the
ribosome with a macrolide antibiotic bound in the NPET.
DISCUSSION
In our experiments, we interrogated one of the most com-
mon problematic motifs for the macrolide-bound ribosome,
Figure 4. Simultaneous Replacement of the First and Last Amino
Acids of the R/K-X-R/KMotif to the Negatively Charged Amino Acids
Prevents ERY-Dependent Translation Arrest
Toeprinting analysis of ERY-dependent ribosome stalling at the templates
encodingMDLD andMELE peptides. The full sequences of theWT andmutant
ermDL ORF and the encoded peptides are shown above the gel. The penul-
timate (1) amino acid residue of the nascent chain in the drug-stalled ribo-
some, the P site, and the A site residues are marked above the peptide
sequence. Black arrows indicate ERY-dependent translation arrest at the Leu
codon. Gray arrows indicate the toeprint bands representing ribosomes
captured at the downstream Pro5 codon because of the presence of mupir-
ocin in the reaction mixture, which inhibits the Ile-tRNA formation. Sequencing
lanes are marked. The shown gel is representative of two independent ex-
periments.R/K-X-R/K, and found that specific physicochemical properties
of substrates participating in peptide bond formation are thema-
jor contributing factors to drug-induced translation arrest.
During translation elongation, macrolides act as inhibitors of
peptide bond formation between specific combinations of PTC
donor and acceptor substrates (Kannan et al., 2014). This
mode of action is possibly mediated by allosteric changes in
the PTC induced by the drug (Sothiselvam et al., 2014). In addi-
tion, direct interactions between the nascent chain and the anti-biotic in the NPET may also modulate antibiotic action (Arenz
et al., 2014a, 2014b; Va´zquez-Laslop et al., 2010) and may at
times allow the drug-bound ribosome to bypass a problematic
motif (S.S., unpublished data). Such influence of the context
likely explains why, in macrolide-treated cells, no significant
increase in ribosome density is observed at some of the R/K-
X-R/K sequences (Davis et al., 2014; Kannan et al., 2014). Our
use of the shortest known peptide capable of directing macro-
lide-dependent ribosome stalling, MRL (Sothiselvam et al.,
2014), allowed us to significantly simplify the system by mini-
mizing the influence of the N-terminal context on the drug-
induced arrest. Furthermore, the small size of the stalling peptide
made it possible to probe the contribution of each of its residues
(with the exception of the N-terminal formyl-methionine) to trans-
lation arrest.
Strikingly, in the context of the short donor substrate, the
physicochemical characteristics of only one of its residues, the
penultimate amino acid, are critical. The properties of the C-ter-
minal amino acid, which directly participates in peptide bond for-
mation, are of lesser importance. Our comprehensive mutational
analysis showed that the simultaneous presence of Lys or Arg
residues in the penultimate position of the peptide and in the
acceptor substrate is sufficient for preventing fast peptide
bond formation in the macrolide-bound ribosome. Subsequent
biochemical studies that utilized different peptidyl donors (MRL
and MAL) and a series of synthetic acceptors showed that the
positive charge of the critical amino acid residues and the size
of their side chains are the key factors that render peptide
bond formation inefficient in the drug-bound ribosome. The posi-
tively charged, long side chain acceptors of the MRL peptide
(ACCA-N-Arg, -Lys, or -ornithine) reacted extremely slowly,
whereas shortening of the positively charged side chain
(ACCA-N-aminoalanine) or removal of the charge increased the
reaction rate, with the most dramatic acceleration achieved
with short uncharged acceptor substrates (Figure 3). Impor-
tantly, substituting the electroneutral Ala for Arg in the penulti-
mate position of the donor (MAL) had a similar effect.
Although the contribution of the size of the side chain in natural
substrate analogs could be generally concealed because of the
dominance of the charge effect, it might nevertheless play a role
in the effects of the drugs on cellular translation. Indeed,
although, in our in vitro experiments, both ACCA-N-Lys and
ACCA-N-Arg reacted too slowly to accurately distinguish the dif-
ference in their reactivity, ribosome profiling analysis showed a
more pronounced enrichment of Arg-containing sequences of
the R/K-X-R/Kmotif in the sites of macrolide-induced translation
stalling (Davis et al., 2014; Kannan et al., 2014). Because the gua-
nidinium group of Arg and the ε-amino group of Lys are both
completely protonated at physiological pH, it is generally
possible that the longer side chain of Arg (six atoms) compared
with Lys (five atoms) accounts for a more severe translation
arrest at the Arg-containing motifs.
Our findings provide an explanation for a long-known fact: that
translation of poly(A) RNA, encoding poly-lysine, is efficiently in-
hibited by erythromycin and results in accumulation of short (di-
to penta-lysine) peptides (Mao and Robishaw, 1971; Otaka and
Kaji, 1975; Vazquez, 1966). Because the poly(Lys) sequence
conforms to the R/K-X-R/K motif, it is not surprising that itsCell Reports 16, 1789–1799, August 16, 2016 1795
synthesis would be interrupted by macrolides at the very early
rounds because the drugs should block the transfer of even
very short nascent chains carrying Lys in the penultimate posi-
tion to the incoming Lys-tRNA.
Our results show that the interplay of the penultimate residue
of the nascent peptide and the incoming amino acid has a dra-
matic effect on macrolide-induced arrest at the R/K-X-R/K sites.
The nature of the C-terminal residue of the donor peptide that re-
sides in the PTC P site appears to be far less significant, at least
in the case of ERY-induced arrest with the minimal peptide (Fig-
ure 1B). Nevertheless, from the somewhat varying relative inten-
sity of the arrest bands in the toeprint gels (Figure 1B), it could be
inferred that the C-terminal residue does modulate, to some
extent, the efficiency of peptide bond formation in the macro-
lide-bound ribosome. The influence of the C-terminal peptide
residue could account for the varying extent of enrichment of
different R/K-X-R/K sequences at the sites of ERY-induced ar-
rest observed in ribosome profiling experiments (Kannan et al.,
2014). Furthermore, the nature of the tunnel-bound antibiotic af-
fects the importance of the C-terminal residue of the nascent
chain for translation arrest. Although Leu3-to-Ala replacement
had only a negligible effect on the transfer of the MRL peptide
to Arg-tRNA in the ERY- or AZI-bound ribosome, the same mu-
tation notably diminished translation arrest when the fluoroketo-
lide SOL was bound (Figure S2). This result is reminiscent of our
recent finding that the nature of the C-terminal residue of another
stalling regulatory peptide, ErmBL, which conforms to a different
stalling motif, XDK (Kannan et al., 2014), determines whether
macrolides or ketolides are recognized as the stalling cofactor
(Gupta et al., 2016).
Several scenarios could account for the slow transfer of a
peptidyl donor with a positively charged penultimate residue
to a positively charged acceptor in the ERY-bound ribosome.
One possibility is that electrostatic repulsion between the
incoming amino acid and the penultimate nascent peptide res-
idue, possibly exacerbated by direct steric hindrance and a
close proximity of the charges located at the ends of the
extended side chains, prevents proper accommodation of the
aminoacyl-tRNA acceptor in the PTC A site (Arenz et al.,
2014a, 2014b; Gupta et al., 2016; Ramu et al., 2011). This could
lead to either an aberrant placement of the stably bound ami-
noacyl-tRNA or to rapid dissociation of Arg- or Lys-tRNA
from the A site. It is also possible that binding of the positively
charged substrate to the A site displaces the peptidyl-tRNA in
the P site when its penultimate position is occupied by a posi-
tively charged residue. Finally, both the donor and acceptor
substrates could be mutually misaligned in the PTC active
site, which would be detrimental for efficient peptide bond
formation.
Although the charge of the amino acids in the donor and
acceptor substrates plays the key role in macrolide-induced ar-
rest, only positively charged residues were detrimental for pep-
tide bond formation. Simultaneous replacement of both of the
critical residues with negatively charged amino acids was not
conducive to translation arrest (Figure 4). It is thus obvious
that the polarity of the charge of the donor and acceptor is
central to the mechanism of stalling. In agreement with this
conclusion, although R/K-X-R/K is one of the most predominant1796 Cell Reports 16, 1789–1799, August 16, 2016macrolide stalling motifs in Gram-positive and Gram-negative
bacteria (Davis et al., 2014; Kannan et al., 2014), no particular
enrichment of the D/E-X-D/E sequences at the sites of drug-
induced translation arrest has been noted. The strict polarity
requirement suggests that electrostatic interactions of the sub-
strates with additional charged group(s) in the ribosome or its li-
gands could be involved in the mechanism of stalling. It is
conceivable that the positive charge at the end of the extended
side chain of the (1) residue of the peptidyl donor or aminoacyl
acceptor could interact with the electronegative phosphate
group of one of the neighboring 23S rRNA nucleotides. The
generally electronegative potential of the NPET could be also
a contributing factor (Lu et al., 2007). Alternatively, the proton-
ated 30 dimethyl-amino group of the macrolide molecule could
influence the placement of the positively charged substrates
in spite of the 8-A˚ distance that separates it from the PTC
active site.
The rate of the catalytic step of peptide bond formation in the
drug-free ribosome depends on the nature of the reacting sub-
strates (Bourd et al., 1982; Johansson et al., 2011; Monro et al.,
1968; Muto and Ito, 2008; Wohlgemuth et al., 2008). However,
this difference in reactivity is normally masked by the slow
rate of aminoacyl-tRNA binding and accommodation, which is
the rate-limiting step of translation elongation (Wintermeyer
et al., 2004). It is conceivable, however, that, if the general cat-
alytic capacity of the PTC is decreased, then formation of pep-
tide bonds between certain generally sluggish substrates could
slow down sufficiently to become rate-limiting. From this stand-
point, it is remarkable that, even in the absence of antibiotic, the
reaction of the MRL peptide with the acceptor analogs carrying
positively charged amino acids with extended side chains was
notably slower that the reaction with electroneutral acceptors
(Table 1). This observation hints that peptide bond formation be-
tween substrates conforming to the R/K-X-R/K motif is intrinsi-
cally slow. Therefore, macrolide antibiotics do not convert well
behaved substrates into slow reactants. Rather, the drugs
amplify the problem of the substrates that are inherently difficult,
making peptide bond formation rate-limiting. We are fully aware,
however, that the use of the artificial acceptor substrates may
significantly aggravate the difference in their reactivity (Brunelle
et al., 2006; Katunin et al., 2002). Furthermore, the kinetic pa-
rameters obtained in the cell-free setting with the use of model
substrates reflect only the general trend in relative substrate
reactivity rather than the actual kinetics of transpeptidation,
which should be much faster when the full-length tRNA delivers
the acceptor amino acid to the PTC A site (Wohlgemuth et al.,
2008). Indeed, the lack of pronounced ribosome stalling at the
R/K-X-R/K motif in the absence of antibiotic (Davis et al.,
2014; Kannan et al., 2014; Li et al., 2012; Mohammad et al.,
2016) suggests that, even for these slow substrates, the rate
of transpeptidation in the living cell is not rate-limiting. There-
fore, it is possible that inhibition of translation by macrolide
antibiotics reveals a general but concealed phenomenon of
the dependence of the rate of peptidyl transfer on the interplay
of the penultimate residue of the nascent chain and the
incoming amino acid.
Other sequence motifs conducive to macrolide action that do
not conform to the R/K-X-R/K consensus are also confined to
amino acid residues residing at or near the PTC. The features of
those substrates that make them difficult for the drug-bound
ribosome are currently unknown. Interestingly, however, one of
the identified macrolide motifs (XPX) (Davis et al., 2014; Kannan
et al., 2014) includes proline, a particularly slow participant in
peptide bond formation (Johansson et al., 2011), especially in
specific contexts (Doerfel et al., 2013; Ude et al., 2013). There-
fore, our conclusion that macrolides exacerbate the problematic
nature of the inherently difficult sequences could expand beyond
the specific example of the R/K-X-R/K motif explored in this pa-
per. Further exploration of the context specificity of macrolide
action might reveal new hidden features of the general mecha-
nisms of protein synthesis.
EXPERIMENTAL PROCEDURES
Reagents
Erythromycin, azithromycin, and mupirocin were from Sigma-Aldrich, solithro-
mycin was provided by Dr. Fernandes (CEMPRA Pharmaceuticals), and indol-
mycin was from Santa Cruz Biotechnology. The reverse transcriptase used in
the toeprinting analysis was purchased from Sigma-Aldrich. All DNA primers
(listed in Table S1) were synthesized by IDT.
The synthesis of ACCA-N-X substrates is described in the Supplemental
Experimental Procedures.
Toeprinting Assay
Linear DNA templates (0.5–1 pmol) encoding the ORF of interest preceded by
the T7 promoter sequence were generated by PCR using the primers indicated
in Table S1. To capture the ribosomes that escaped ERY-dependent arrest at
theRLR sequence, an Ile codon (Ile6) was introduced after the Pro5 codon, and
all reactions were carried out in the presence of 50 mMmupirocin, an IleRS in-
hibitor. In the templates where the codons of the motif were mutated to specify
Ile, the Ile6 codonwas replacedwith aTrp codon, and, in these cases, reactions
were carried out in the presence of indolmycin, an inhibitor of TrpRS.
Templates were used to direct coupled transcription-translation in the
PURExpress cell-free system (New England Biolabs). The reactions were per-
formed in a total volume of 5 ml and, where indicated, were supplemented with
antibiotics (50 mM final concentration). Following 10-min incubation at 37C,
the primer extension reaction was initiated by addition of the primer NV1 (Table
S1) and 3 U of reverse transcriptase. The resulting cDNA products, along with
sequencing reactions, were separated in a 6% sequencing gel and visualized
with a Typhoon imager (GE Healthcare).
In Vitro Peptidyl Transfer Reaction
Synthetic mRNAs (synthesized by Thermo Fisher) encoding MRL peptide
(ATAAGGAGGAAAAAATATGAGACUU, the coding sequence is underlined)
or MAL peptide (ATAAGGAGGAAAAAATATGGCACUU) were used for in vitro
translation in the PURE system. The 5-ml reactions containing 75 pmol of the
mRNA template were supplemented with 1 mCi [35S]-methionine (specific ac-
tivity, 1,175 Ci/mmol) and, where indicated, 50 mMERY. Following 7-min incu-
bation at 37C, thiostrepton was added to the final concentration of 50 mM to
prevent further rounds of translation. The synthetic acceptor substrate
ACCA-N-X, dissolved in water, was then added to a final concentration of
0.7 mM. Aliquots (5 ml) were withdrawn at different times and immediately
mixed with an equal volume of SDS-containing tricine sample buffer (Bio-
Rad). Reaction products were resolved in 16% Bis-Tris polyacrylamide gel
as described previously (Va´zquez-Laslop et al., 2008). Gels were fixed, dried,
exposed to a phosphorimaging screen, and visualized with a Typhoon imager
(GE Healthcare).
Quantification of the peptidyl-tRNA bands was performed using ImageJ
(Schneider et al., 2012). Because the reactions contain excess of [35S]-methi-
onine and fMet-tRNAMet is continuously regenerated in the reaction, the fMet-
tRNAMet band served as the loading control and normalization factor. The
normalized peptidyl-tRNA band at t = 0, which represents the total amountof unreacted peptidyl-tRNA before addition of the A site substrates, was set
at 100%. The progress of the reaction was monitored by quantifying the
amount of unreacted peptidyl-tRNA at experimental time points. The data
were fitted to one phase exponential decay model in GraphPad PRISM using
the equation
Y= ðY0 PLÞexpð kXÞ+PL;
where Y is the amount of unreacted peptidyl-tRNA (percent) at any given time
point, Y0 is the initial amount of unreacted peptidyl-tRNA at t = 0, PL (plateau)
is the Y value at infinite times (calculated in PRISM), k is the rate constant, and
X is the time in minutes. The error range of the apparent rate constants shown
in Table 1 represents the SEM.
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